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Abstract: Fragile X-associated tremor/ataxia syndrome (FXTAS) is a progressive neurological 
disorder that affects older adult carriers, predominantly males, of premutation alleles (55 to 200 
CGG repeats) of the fragile X (FMR1) gene. Principal features of FXTAS are intention tremor, 
ataxia, parkinsonism, cognitive decline, and peripheral neuropathy; ancillary features include, 
autonomic dysfunction, and psychiatric symptoms of anxiety, depression, and disinhibition. 
Although controlled trials have not been carried out in individuals with FXTAS, there is a 
signifi cant amount of anecdotal information regarding various treatment modalities. Moreover, 
there exists a great deal of evidence regarding the effi cacy of various medications for treatment 
of other disorders (eg, Alzheimer disease) that have substantial phenotypic overlap with FXTAS. 
The current review summarizes what is currently known regarding the symptomatic treatment, 
or potential for treatment, of FXTAS.
Keywords: fragile X syndrome, dementia, ataxia, neurodegeneration, parkinsonism, tremor
Introduction
Fragile X-associated tremor/ataxia syndrome (FXTAS) is seen in a subgroup of older 
adults who are carriers of premutation alleles (55–200 cytosine, guanine and guanine 
[CGG] repeats) of the fragile X mental retardation 1 (FMR1) gene (Hagerman et al 
2001; Berry-Kravis et al 2007; Jacquemont et al 2007; Leehey et al 2007). The patho-
genesis of FXTAS results from the direct neural cell toxicity of elevated levels of the 
expanded-CGG-repeat FMR1 mRNA (RNA toxic gain-of-function), which leads in 
turn to dysregulation of a number of proteins including lamin A/C and alpha B crystal-
lin (Arocena et al 2005). Characteristic neuropathological fi ndings of FXTAS include 
formation of inclusions in neurons and astrocytes throughout the brain; spongioform 
white matter changes in subcortical, periventricular and brainstem regions, including 
the middle cerebellar peduncles (MCP sign); and global brain atrophy (Greco et al 
2002; Jacquemont et al 2003; Cohen et al 2006; Greco et al 2006). The natural history 
of FXTAS begins with the onset (average age, 60 yr) of a movement disorder involv-
ing intention tremor and/or gait ataxia with tremor often preceding the ataxia by one 
to several years (Leehey et al 2007). Decline in mobility generally progresses through 
the use of a cane, walker, and wheelchair, with eventual inability to ambulate (Leehey 
et al 2007). FXTAS also includes neuropathy in the majority of patients, often involv-
ing pain, particularly in the lower extremities (Jacquemont et al 2004; Berry-Kravis 
et al 2007; Hagerman et al 2007).
Additional features include autonomic dysfunction involving impotence, hyperten-
sion, orthostatic hypotension, urinary frequency, and urinary and bowel incontinence 
(in the later stages). Psychiatric problems commonly seen in patients with FXTAS 
include anxiety, agitation, apathy, and depression (Bacalman et al 2006). However, 
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a subgroup of premutation carriers may have psychiatric 
problems even in childhood or adolescence, with features that 
can include ADHD, obsessive/compulsive thinking, anxiety 
disorders, or social diffi culties (Cornish et al 2005; Farzin 
et al 2006; Hessl et al 2006). Cognitive changes in patients 
with FXTAS include executive function defi cits and memory 
problems, which may be present at the time the individual 
is diagnosed with tremor and/or ataxia (Grigsby et al 2006, 
2007). The cognitive changes progress at a variable rate 
and dementia develops in at least 50% of cases (Bourgeois 
et al 2007).
Premutation alleles of the FMR1 gene are relatively 
common in the general population, carried by ~1 in 130–250 
females and ~1 in 500–800 males (Rousseau et al 1995; Pesso 
et al 2000; Dombrowski et al 2002; Beckett et al submitted). 
FXTAS occurs in older carriers (50 years), is more common 
in males, and has age-dependent penetrance: 17% in their 
50s, 38% in their 60s, 47% in their 70s, and 75% in their 80s 
(Jacquemont et al 2004). These numbers lead to an estimated 
prevalence of FXTAS as approximately 1 in 8,000 males 
over 50 years in the general population (Jacquemont et al 
2004, 2007). A recent study in female carriers suggests that 
4% overall and 8% over 50 years of age develop FXTAS, 
but it has a milder course than in males, perhaps related to 
a protective effect of the second (normal) X chromosome in 
females (Jacquemont et al 2004; Coffey et al in press).
Recent studies have broadened our concept of FXTAS 
to include hormonal dysfunction. Inclusions have been 
documented in the anterior and posterior pituitary (Louis 
et al 2006; Greco et al 2007), and in the Leydig cells in the 
testicles, which produce testosterone. In one study, testoster-
one defi ciency was reported in 5 of 8 carriers that were tested, 
with such reductions presumably related to the pituitary 
and Leydig cell involvement (Greco et al 2007). Additional 
hormonal problems including hypothyroidism are seen in 
approximately 50% of women with FXTAS (Coffey et al in 
press). Fibromyalgia is seen in 40% of women with FXTAS, 
although the pain associated with that patient description may 
be diffi cult to distinguish from painful neuropathy (Coffey 
et al in press).
It has been known since 1991 that approximately 20% 
of women with the premutation have premature ovarian 
failure (Cronister et al 1991), with the frequency of this 
fi nding more recently shown to correlate with the size of 
the CGG expansion in the premutation range (Sullivan et al 
2005). Features of FXTAS, including age of onset of tremor 
and ataxia (Tassone et al 2007), severity of both tremor 
and ataxia, overall motor impairment (Leehey et al 2007), 
severity of brain atrophy, and white matter disease (Loesch 
et al 2005; Cohen et al 2006), the density of inclusions and 
the age of death (Greco, Berman et al 2006), all correlate 
with the CGG repeat number.
The diagnosis of FXTAS is made clinically utilizing 
criteria set forth in Jacquemont and colleagues (2003) 
which can be seen in Table 1. Defi nite FXTAS requires 
the presence of the major radiological sign, white matter 
disease in the MCP, in addition to tremor and/or ataxia in a 
premutation carrier. On autopsy, the presence of eosinophilic 
(ubiquitin-positive; tau-, synuclein-negative) inclusions in 
the nuclei of neurons and astrocytes is also characteristic of 
defi nite FXTAS, and has been added to the diagnostic criteria 
(Hagerman and Hagerman 2004). However, the MCP sign is 
only seen in 60% of males with FXTAS (Cohen et al 2006), 
and in approximately 13% of females with FXTAS (Adams 
et al 2007). Individuals with the premutation with tremor 
and ataxia but without the MCP sign (including those who 
have not had an MRI or cannot have an MRI) are described 
as probable FXTAS. Those with fewer symptoms, such as 
tremor or ataxia only, are described as possible FXTAS 
(Table 1).
Table 1 Clinical diagnostic criteria for FXTAS (Adapted from 
Jacquemont et al 2003)
Molecular CGG repeat 55–200
Clinical
Major Intention tremor
Gait ataxia
Minor Parkinsonism
Moderate to severe short term memory defi ciency
Executive function defi cit
Radiological
Major MRI white matter lesions involving middle 
cerebellar peduncles
Minor MRI white matter lesions involving cerebral
white matter
Moderate to severe generalized brain atrophy
Diagnostic categories
Defi nite Probable Possible
One major clinical, 
And either One 
major radiological, 
or Presence of 
intranuclear inclusions 
(Hagerman and 
Hagerman 2004) 
Two major clinical; or 
One minor clinical, and 
One major radiological
One major clinical, 
and One minor 
radiological
Abbreviations: FXTAS, fragile X-associated tremor ataxia syndrome; CGG, cytosine, 
guanine and guanine; MRI, magnetic resonance imaging.
Clinical Interventions in Aging 2008:3(2) 253
Treatment of FXTAS
There is currently no targeted therapeutic intervention that 
can arrest or reverse the pathogenesis of FXTAS; however, 
there are a number of treatment approaches of potential 
symptomatic benefi t, and these are reviewed here. Moreover, 
there are neuroprotective agents that may slow the course 
of FXTAS. We emphasize that no randomized, controlled 
clinical trials have yet been carried out specifi cally in indi-
viduals with FXTAS for any therapeutic agent or procedure, 
given its relatively recent discovery. Therefore, the current 
review must be considered as a summary of experiential 
reports by patients with FXTAS and their medical provid-
ers, or as summaries of the effi cacies of agents/procedures 
that have proven to be effective in other disorders that have 
signifi cant symptom overlap with FXTAS (Jacquemont et al 
2004; Bourgeois et al 2006; Hall et al 2006). Clearly, what is 
necessary at this point is to establish controlled clinical trials 
for these interventions in patient populations with FXTAS.
Treatment of tremor
Fifty-six patients with FXTAS completed a questionnaire to 
determine if any medications had been effective for neuro-
logical symptoms (Hall et al 2006). This was followed by a 
record review of treatment of their neurological symptoms. 
Although 70% of patients with defi nite FXTAS were on 
medications for their neurological symptoms, only 30% of 
patients with possible or probable FXTAS were taking medi-
cations for motor signs (tremor, ataxia, or parkinsonism). Of 
the subjects receiving therapy for action tremor; 3/6 reported 
mild to moderate improvement on primidone, 3/8 had 
moderate improvement of tremor on beta-blockers, 2/8 had 
moderate improvement on benzodiazepines. One subject 
had improved tremor on memantine, which was prescribed 
for cognitive decline. There was no improvement in tremor 
for two subjects on gabapentin.
Beta-blockers and primidone are commonly used to treat 
essential tremor (ET) and may be the most likely candidates 
for initiating therapy in FXTAS. Because controlled studies 
have not been carried out in FXTAS, we discuss data from the 
ET treatment literature. Propranolol, a β-adrenergic blocker, 
is the most effective medication for the treatment of ET and 
may help enhanced physiologic tremors as well (Caccia et al 
1989; Calzetti et al 1990); however, these medications are 
contraindicated in patients with asthma, second-degree AV 
block, and insulin dependent diabetes. Fatigability, impo-
tence, lightheadedness, sedation and depressive symptoms 
are common side effects. Primidone has also been shown 
to be effective in placebo controlled studies in ET (Koller 
and Royse 1986), with its anti-tremor effect attributed to its 
metabolite phenobarbitol (Sasso et al 1991). It is started at 
low doses (eg, 25 mg/day or less), to minimize side effects 
such as nausea, vomiting, sedation, worsening of motor coor-
dination, and confusion. If propanolol and primidone are not 
benefi cial, second line treatment includes topiramate, an anti-
convulsant with tremor effi cacy in placebo-controlled trials. 
Sotalol, atenolol (other beta-blockers that may have less side 
effects than propanolol), and alprazolam, a benzodiazepine 
that is also reported to be effective in some patients, may also 
be considered (Gunal et al 2000). Because tremor is exacer-
bated by anxiety or stress in most disorders, benzodiazepines 
may help to reduce anxiety and reduce tremor secondarily. 
If these treatments fail, other medications that may be help-
ful and have shown some effectiveness in open-label trials 
include botulinum toxin, levetiracetam (Bushara et al 2005), 
clonazepam, clozapine, nadolol, and nimodipine (Zesiewicz 
et al 2005). In a single open-label study levetiracetam was 
found to be helpful for cerebellar tremor (Striano et al 2006). 
The latter is relevant for FXTAS because cerebellar dysfunc-
tion is a prominent fi nding in many affected persons.
In Hall and colleagues (2006), rest tremor was not evalu-
ated exclusively, but FXTAS patients with parkinsonism 
(rest tremor, slowness, or stiffness) improved on carbidopa/
levodopa in 4/10 subjects, pramipexole in 3/6 subjects, and 
in one patient on eldepryl (Hall et al 2006). Although par-
kinsonism is considered a minor criteria for FXTAS, some 
patients are dopamine responsive making them similar to 
patients with idiopathic Parkinson disease. It is unknown 
whether motor fl uctuations, dyskinesia, or other side effects 
of these medications occur in patients with FXTAS, but 
dopaminergic therapy should be considered if parkinsonism 
is problematic in a patient with FXTAS.
Botulinum toxin injections
Botulinum toxin (BTX) is most commonly used in treating 
conditions that involve involuntary muscle activities, such 
as dystonia and spasticity. Its indications, though not all yet 
approved, have expanded during recent years, to include its 
use in the management of oversecretion of sweat glands, 
hypersalivation, and tremors (Cordivari et al 2004). On 
a trial basis, we applied BTX in one of our patients with 
FXTAS with a disabling arm tremor. Under the guidance of 
electromyography (EMG), 10–15 units of Botox (the type A 
of BTX, BTX A) were injected into fl exor digitorum super-
fi cialis, fl exor digitorum profundus, and extensor digitorum. 
The exact dosage of BTX injected was determined based 
on the real-time activities shown on EMG, which provides 
anatomical guidance for injections. The injection protocol 
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was repeated every three months on average. The patient 
experienced signifi cant functional improvement following 
the injections, with reduced tremor during action and at rest 
one week later. The maximal effect of BTX was experienced 
at 4–6 weeks post injections, and benefi t lasted up to three 
months on average.
Placebo controlled trials of BTX in essential tremor have 
shown that in some cases there is signifi cant reduction of 
tremor amplitude, but only mild functional improvement 
associated with problematic limb weakness (Jankovic et al 
1996; Brin et al 2001; Cordivari et al 2004). Faced with the 
challenge of medical management of the disabling tremor in 
patients with FXTAS, further study in this disorder, including 
controlled trials, are warranted.
Deep brain stimulation
Only three persons with FXTAS that underwent bilateral 
thalamic deep brain stimulation for tremor have been reported 
(Leehey et al 2003; Peters et al 2006). In one, a transient 
microthalamotomy effect improved tremor greatly but speech 
was softer and gait ataxia worsened markedly (Leehey et al 
2003). Tremor reoccurred in four months, and stimulation 
then was not benefi cial due to an open circuit on one side and 
suboptimal electrode placement on the other. The electrodes 
were not corrected because of concern that further surgery 
may worsen speech and ataxia. There was no long-lasting 
cognitive dysfunction from the surgery. The two other people 
were cousins (Peters et al 2006). No informative clinical data 
were available on one; the other had a marked reduction in 
tremor while gait ataxia persisted postoperatively. This latter 
patient had mild executive dysfunction prior to surgery and 
there was no mention about any changes in his mentation 
postoperatively.
Given these reports suggesting gait ataxia may worsen 
after surgery, the usefulness of this procedure in FXTAS may 
be limited. Moreover, persons with preexisting cognitive dys-
function tend to dement after bilateral deep brain stimulation 
(Aybek and Vingerhoets 2007), and persons with FXTAS 
frequently have signifi cant cognitive dysfunction, further 
dampening enthusiasm for using this procedure in this popu-
lation. However, persons with little or no ataxia or cognitive 
defi cits, but with disabling medically resistant tremor may still 
be candidates, at least for unilateral surgery, which is less likely 
to worsen ataxia and cognition than bilateral surgery.
Computer modifi cations
Several approaches to the problem of the use of the com-
puter mouse by individuals with essential tremor have been 
tried with varying degrees of success. One is to reduce the 
physical tremor by mechanical means, such as adding mass 
and/or some form of damping to the mouse. Although this 
can be helpful for some people, such a mouse can be physi-
cally tiring to use. Furthermore, it is diffi cult to adjust the 
mass and damping to a particular individual’s needs, which 
may vary over time and circumstance. A second approach 
is to use a different type of pointing device, such as a track-
ball, job stick, or keyboard keys. This helps some people, 
but not others. For example, using a trackball requires good 
fi nger dexterity, while certain types of joysticks can actu-
ally increase the tremor. A third approach, which was taken 
in a study completed at the University of Colorado Health 
Sciences Center, is to accept the mouse motion and apply a 
digital smoothing algorithm to reduce its effects. Researchers 
at the IBM Watson Research Center created the Assistive 
Mouse Adapter (www.montrosesecan.com) algorithm which 
has demonstrated a positive difference in cursor movement, 
button clicking, and speed of use in patients with tremor 
although none had FXTAS (Bodine et al 2007).
Treatment of ataxia
Gait difficulties may be caused by cerebellar ataxia or 
parkinsonism in FXTAS and can be exacerbated by 
peripheral neuropathy. In those with parkinsonism and 
gait abnormalities, subjective improvement was seen on 
carbidopa/levodopa, dopamine agonists, and eldepryl as 
mentioned above (Hall et al 2006). Ataxia improved in one 
patient on amantadine in the Hall and colleagues (2006) 
report and in two patients reported by Jacquemont and 
colleagues (2004). There is no universally effective treat-
ment for cerebellar ataxia, but a small proportion of sub-
jects on amantadine or buspirone will show improvement. 
Unfortunately, these medications may be poorly tolerated in 
ataxia patients (Hassin-Baer et al 2000).
In addition to pharmacological treatment, physical 
therapy can be helpful for improving strength and gait in 
treatment of patients with ataxia and parkinsonism, particu-
larly as these patients continue to age (Ellis et al 2005; Cao 
et al 2007). Patients with cerebellar ataxia tend to exhibit 
gait abnormalities including slower walking velocity with 
reduced step length and high variability in step timing and 
amplitude (Ebersbach et al 1999). Researchers have found 
that the variability in gait speed is more attributable to bal-
ance-related defi cits than intra-limb coordination of leg 
placement during walking (Morton and Bastian 2003; Ilg 
et al 2007). Traditionally, patients with Parkinsonism have 
responded well to step and gait training in physical therapy. 
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Lasting improvements in overground walking speed, stride 
length, cadence, and fall reduction have been seen with physi-
cal therapy and particularly with body-weight-supported 
treadmill training (Miyai et al 2002; Pohl et al 2003; Protas 
et al 2005). In our experience these approaches have been 
helpful for individuals with FXTAS, but no studies of effi cacy 
have been reported yet.
Treatment of cognitive defi cits
and dementia
The treatment of cognitive impairment in FXTAS is based on 
off-label application of dementia treatments conventionally 
used in Alzheimer’s disease (Farlow and Cummings 2007). 
Cautious dosing of donepezil and other cholinesterase inhibi-
tors can be considered for the memory impairment; in the 
early weeks and months of treatment memory function may 
be enhanced. Even if the eventual course of memory and 
other cognitive decline is not substantially altered, short-term 
improvement in quality of life can result (Bourgeois et al 
2006). In addition, the frequent co-morbidities of depressive, 
anxiety, and psychotic disorders may lead the clinician to 
treat with antidepressants and/or antipsychotics. The positive 
treatment effects on mood, anxiety, and psychosis can also 
result in improved cognitive symptoms and performance 
as seen in a case report of FXTAS (Bourgeois et al 2006). 
Anecdotal information also suggests that memantine, which 
may decrease glutamate-mediated neurotoxicity (Choi et al 
1988), is helpful in FXTAS, but controlled studies have not 
been carried out. Memantine is typically well tolerated when 
started at low-dose (ie, 5 mg every morning) with a gradual 
increase to 10 mg twice a day (Reisberg et al 2003). Ran-
domized trials are currently being planned for cholinesterase 
inhibitors, memantine, and other putatively neuroprotective 
(eg, lithium) agents to address the effect of these medications 
on both the clinical symptoms and the eventual prognosis for 
the cognitive aspects of FXTAS (Bauer et al 2003; Chuang 
2004).
While it has yet to be established in clinical trials, using 
the example of other neurodegenerative diseases (Scarmeas 
et al 2005; Aggarwal et al 2006), it may be that progression 
in the motor symptoms predicts similar deterioration in the 
cognitive symptoms. Thus, clinicians should be particularly 
vigilant for cognitive symptoms if the tremor and ataxia 
symptoms are in a period of progression.
Evaluation for other causes of dementia, particularly 
reversible contributing causes, such as hypothyroidism, HIV, 
syphilis, B12 defi ciency, thiamine, B6, or folate defi ciency, is 
essential. Patients with FXTAS will usually have signifi cant 
brain atrophy with dilatation of the ventricles, which may 
be mistaken for normal pressure hydrocephalus (NPH). 
However, surgery for presumed NPH has been disastrous in 
cases of FXTAS (Jacquemont et al 2004). Typically patients 
with FXTAS do not tolerate surgery with general anesthesia 
well and further deterioration in both motor and cognitive 
abilities is typically seen (Jacquemont et al 2004). There-
fore, surgery should be avoided if at all possible. Support 
for family caretakers during the dementia process is crucial, 
and the decision to place a patient with FXTAS in a center 
that delivers specialty care for dementia patients is often 
eventually necessary in late-stage disease.
Nutrition and exercise studies
in related conditions
Many studies have investigated the possible role of diet and 
exercise in Alzheimer’s disease (AD), dementia, and related 
conditions. It is likely that the defi ciencies discussed here will 
impact patients with FXTAS just as they do other causes of 
dementia. Defi ciencies in B vitamins, particularly folate and 
vitamin B12, are common in elderly populations and have 
been associated with increased risk of cognitive impairment 
and dementia (Clarke et al 1998; Ramos et al 2005; de Lau 
et al 2007; Durga et al 2007). Of particular interest is the 
sulfur amino acid homocysteine, which becomes elevated in 
the blood (hyperhomocysteinemia) when folate or vitamin 
B12 is defi cient (Selhub and Miller 1992). Hyperhomocys-
teinemia is an independent risk factor for vascular disease, 
including cerebrovascular disease (Refsum et al 1998), and 
is associated with both an increased prevalence and incidence 
of AD and dementia (Clarke et al 1998; Miller et al 2002; 
Seshadri et al 2002; Haan et al 2007). Lowering plasma 
homocysteine levels with B vitamin supplements may reduce 
the risk, though clinical trials are necessary to determine 
if such interventions will ultimately benefi t patients with 
FXTAS or AD (Luchsinger et al 2007). It may be the case 
that preventing hyperhomocysteinemia before cognitive 
defi cits appear will be more benefi cial than intervening after 
cognitive impairment has been manifested.
Alternatively, defi ciencies of folate and vitamin B12 
may have effects on brain function independent of homo-
cysteine. Both vitamins are involved in the synthesis of 
S-adenosylmethionine (SAM), which serves as the universal 
methyl donor for a wide variety of methylation reactions, 
including those involving neurotransmitters, membrane 
phospholipids, myelin, and DNA (Selhub and Miller 1992). 
Of note is that both folate and vitamin B12 defi ciencies have 
been associated with depression (Alpert and Fava 1997), 
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and oral supplements of SAM have been shown to alleviate 
depressive symptoms (Mischoulon and Fava 2002). There 
is also some evidence that folate has antioxidant properties 
(Stanger et al 2002), though this is not currently considered 
a major property of the vitamin. Nonetheless, neurons with 
the FXTAS premutation will die more easily with oxidative 
stress, and we recommend folate and B complex supplemen-
tation (to avoid defi ciencies). However, the prevalences of 
folate, vitamin B12, and other B vitamin defi ciencies, as well 
as hyperhomocysteinemia in FXTAS patients are not well-
documented and it is unknown if B vitamin supplements in 
FXTAS patients will protect against the cognitive impairment 
and depression associated with the disorder.
Other dietary factors may be important in FXTAS. Treat-
ment with antioxidants, such as vitamins C and E, may help 
prevent and treat the oxidative damage in neuronal cells 
(Sano 2003).
Exercise can also affect the outcomes of patients with 
AD, FXTAS, and other neurodegenerative diseases and it can 
stimulate neurogenesis. Aerobic exercise has been found to 
modify cognition, such as executive functioning, and reduce 
symptoms of depression and behavioral problems in AD 
patient populations (Yu et al 2006; Rolland et al 2007). We 
recommend exercise for patients with FXTAS, because in 
our clinical experience it has been helpful. An exercise rou-
tine that includes walking, strength, balance, and fl exibility 
training may be therapeutic (Rolland et al 2007). For patients 
experiencing signifi cant tremor, this should be guided by a 
physical therapist, as described above.
Treatment of psychiatric problems
Psychiatric problems can occur prior to the onset of FXTAS, 
and include ADHD, anxiety disorders, and depression in 
a subgroup of carriers. Females have been studied to the 
greatest extent, although the stress of raising a child with 
fragile X syndrome may exacerbate any underlying pathol-
ogy related to the premutation (Franke et al 1996, 1998). The 
limbic system has a higher transcription rate for the FMR1 
mutation than most other areas of the brain and therefore it 
may be the most vulnerable to the RNA toxicity effect of the 
premutation (Hagerman and Hagerman 2004; Tassone et al 
2004). Recent evidence of the association of depression with 
Alzheimer disease suggests that early treatment of psychi-
atric problems, particularly depression and anxiety, which 
can lead to neuronal cell death in the hippocampus, should 
be treated early (Sapolsky 2000). This is likely true for all 
brain diseases but there is a predisposition to depression in 
individuals with the premutation even before the onset of 
FXTAS (Franke et al 1996; Hagerman and Hagerman 2002; 
Hessl et al 2005). In addition, the use of selective serotonin 
reuptake inhibitors (SSRIs) to treat depression or anxiety can 
stimulate neurogenesis in the aging brain and may therefore 
be neuroprotective for later cognitive decline (Jacobs et al 
2000; Santarelli et al 2003). Neurogenesis, the making of 
new neurons in adulthood, only occurs in the olfactory bulb 
and in the dentate gyrus of the hippocampus. The latter is 
important for learning and memory (Jacobs et al 2000). A 
stimulating environment that includes regular exercise may 
enhance neurogenesis, but increased stress or increased levels 
of glucocorticoid hormones (cortisol) is expected to inhibit 
neurogenesis (Jacobs et al 2000). Therefore teaching patients 
to reduce stress and increase exercise as described above 
may be benefi cial for neurogenesis and may be particularly 
helpful in patients with FXTAS.
Integrated psychopharmacological approaches with 
antidepressants and antipsychotics (if needed) along with 
cognition enhancers (discussed above) are indicated. Among 
antidepressants, tricyclics (TCAs) and MAOIs have a pro-
pensity for systemic side effects (anticholinergic effects of 
TCAs may also further compromise cognition) and are best 
avoided. SSRIs with minimal drug-drug interaction profi les 
(eg, sertraline, citalopram, escitalopram) are preferred; 
paroxetine, fl uoxetine, and fl uvoxamine are discouraged 
due to drug-drug interaction risk. The selective serotonin 
norepinephrine reuptake inhibitors (SNRIs; venlafaxine 
and duloxetine) are to be considered, as their noradrenergic 
activity may be desirable. Duloxetine may have the added 
benefi t of reducing pain as described below. Both of these 
medications are used only with caution in renal failure, 
and they have CYP2D6 inhibitory effects so there can be 
interactions with other medications. Mirtazapine is helpful 
especially for sedation and appetite stimulation; its dose is 
usually decreased in renal failure. For psychotic symptoms, 
cautious use of atypical antipsychotics is recommended with 
close follow-up; olanzapine is problematic in diabetes, while 
ziprasidone can be problematic in patients with increased 
QTc. There have been no cases of serious cardiac events 
with any of the atypical antipsychotic drugs (Tandon 2002; 
Harrigan et al 2004). The newer antipsychotic, aripiprazole, 
may have the least metabolic side effects and may be a useful 
choice when needed in patients with FXTAS.
Treatment of autonomic 
dysfunction
Urinary urgency and frequency can be irritating symptoms, 
starting in the early 40’s and slowly become debilitating as 
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the FXTAS patient ages. The normal micturition rate for 
most men is about every three hours with average fl uid intake 
but may progress to every 20 minutes in severely affected 
individuals. Micturition is associated with diffi culty starting 
the stream, diffi culty emptying the bladder and dribbling. 
Detailed urodynamic studies have not been conducted, but 
hyperactive detrusor activity is possible since some patients 
respond well to tricyclic antidepressants or muscarinic 
receptor antagonists. Patients who do not respond well to 
this therapy may be experiencing poor bladder contractility 
or sphincter dyssynergia. In many patients a more effective 
treatment is cystoscopy under local anesthetic with injections 
of 200 cc of Botox into the submucosal lining of the blad-
der in 10 cc aliquots. If a small diameter cystoscope is used 
the procedure is relatively well tolerated. A rare patient will 
develop an inability to urinate, and self-catheterization can 
easily be taught. After Botox injections patients are treated 
with an antibiotic and infections are rare. Mild hematuria usu-
ally resolves within 3 to 5 days. The effects of the botulinum 
can last from 3 to 4 months or longer.
Bowel incontinence is a late effect of FXTAS and may 
start as a slowly progressive dilated and tortuous large bowel 
and result in chronic megacolon as the patient ages. No defi ni-
tive research has been done on patients with FXTAS but it is 
presumed that autonomic anomalies are responsible for these 
signs and symptoms as well as overactive bladder (OAB). 
The treatment of chronic megacolon is laxatives to prevent 
constipation and high fi ber supplements to encourage normal 
peristalsis. A new laxative regimen that is usually reserved 
for short 1–2 week treatments consists of polyethylene glycol 
(17 g in 250 cc of fl uid) once or twice a day, which may need 
to be used for up to a year. Side effects of diarrhea might 
require modifying the dose. The medication is not absorbed 
by the small bowel or colon but acts as an osmotic laxative 
bringing water into the bowel and softening the stool. The 
rationale behind the treatment is to slowly train the bowel 
to constrict down to a more normal size. Further studies of 
this problem in FXTAS are warranted.
Swallowing diffi culties are a common, typically late 
symptom in FXTAS. We have seen one recent case of 
FXTAS with swallowing diffi culties who had an excellent 
response to pyridostigmine bromide, a reversible acety-
cholinesterase inhibitor, which is typically used to enhance 
muscurinic signal transmission in the management of myas-
thenia gravis. Adverse effects are from stimulation of the 
parasympathetic nervous system via muscarinic receptors 
and they can include sweating, salivation, nausea, vomiting, 
diarrhea and abdominal cramping.
Pyridostigmine can also be used for orthostatic 
hypotension (Gales and Gales 2007), which is also common 
in FXTAS. It also enhances sympathetic signal transduction, 
which increases peripheral vascular resistance and increases 
baroreceptor sensitivity, which helps with orthostatic symp-
toms without exacerbating supine hypertension. Other agents 
that may be helpful in some cases for patients with FXTAS 
and orthostatic hypotension, include those often used in 
patients with multiple system atrophy or Parkinson disease 
such as midodrine and fl udrocortisone. Increasing fl uid and 
salt intake can also be helpful if there are no medical contra-
indications (eg, coexisting heart disease or hypertension).
Systemic hypertension is seen in the majority of both 
male and female patients with FXTAS (Jacquemont et al 
2003; Coffey et al in press), and it is thought to be related to 
autonomic dysfunction. It is often seen early, prior to the onset 
of tremor and or ataxia. Because hypertension can lead to 
hypertensive encephalopathy, it is important to treat it early to 
avoid any exacerbation of CNS disease related to FXTAS.
Treatment of hormonal dysfunction
Hypothyroidism is a common problem among females with 
the premutation. A recent study demonstrated that 17% of 
adult women with the premutation had thyroid dysfunction, 
usually hypothyroidism, while 50% of women who had 
FXTAS had thyroid dysfunction, and this was signifi cantly 
different from aged matched controls without the premutation 
(Coffey et al in press). Therefore, routinely testing for thyroid 
dysfunction is indicated on a yearly basis in women with the 
premutation who are older than 50 years and particularly 
those who have neurological problems. Replacement is indi-
cated for hypothyroidism because if left untreated cognitive 
defi cits may occur, and psychiatric problems could be ampli-
fi ed over those that may already be present in premutation 
carriers (Devdhar et al 2007).
We have noted testosterone defi ciency in some patients 
with FXTAS, although no large studies have been conducted 
(Greco et al 2007). We have even seen affected individuals 
become aware of erectile dysfunction before the onset of 
other neurological signs. Low testosterone is only one of 
many causes of male impotence, but it is logical to speculate 
that testosterone replacement may improve libido and sexual 
function in FXTAS patients. Other problems associated with 
FXTAS which might improve include cognition, memory, 
energy level and mood (Cherrier et al 2003; Hagerman and 
Hagerman 2004). Further studies of testosterone defi ciency 
in FXTAS are warranted and the benefi ts of testosterone 
replacement require study.
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Treatment of pain
Pain is a common problem in patients with FXTAS and it 
includes neuropathic pain, particularly in the lower extremi-
ties seen in both males and females (Hagerman et al 2007), 
and fi bromyalgia pain which is more common in females 
with FXTAS (Coffey et al in press). Although neuropathic 
pain is diffi cult to treat, available pharmacologic treatments 
provide meaningful relief for many patients. Neuropathic 
pain is typically refractory to acetaminophen and nonsteroi-
dal anti-infl ammatory drugs. Effective treatments include 
antidepressants, antiepileptics, and topical analgesics (Gilron 
et al 2006). In our experience, treatment with gabapentin or 
pregabalin has proven benefi cial for patients with FXTAS 
and neuropathic pain. In addition, application of Lidoderm 
(lidocaine 5%) patches can provide symptomatic relief 
for peripheral neuropathic pain in the lower extremities 
(Herrmann et al 2005). Up to three patches can be applied 
over intact skin on the affected areas and left in place for up 
to 12 hours over a 24-hour period. Fibromyalgia, chronic 
fatigue syndrome, and irritable bowel syndrome occur com-
monly in female subjects with FXTAS (Coffey et al in press). 
There is no clear separation of these syndromes, which are 
often co-morbid with mood disturbances. Initial treatment 
for fi bromyalgia should include nonpharmacologic treat-
ments such as cardiovascular exercise, cognitive-behavioral 
therapy and/or structured patient education (Goldenberg et al 
2004). The most effective pharmacologic treatments include 
antidepressant, anticonvulsant and/or muscle relaxant medi-
cations (Goldenberg et al 2004). If the above treatments do 
not provide acceptable pain relief, patients should be referred 
to a pain specialty clinic for consideration of interventional 
treatments, pain rehabilitation programs and/or chronic treat-
ment with potent opioid analgesics.
Massage therapy
Tremors can be exacerbated by anxiety and stress, as noted 
earlier, so an important approach to treatment of these 
symptoms would be the reduction of these tremor stimula-
tors. Massage has been shown to be effective in reducing 
cortisol levels, stress and anxiety, as well as improving 
overall mental health (Balint et al 2002; Mannerkorpi and 
Henriksson 2007; Sharpe et al 2007; Tsao 2007). Pain and 
discomfort, also associated with fi bromyalgia, stiffness (eg, 
with parkinsonism), and fatigue are also contributors to 
stress and anxiety. Massage therapy can lessen these types of 
discomforts, as well as decrease uncomfortable sleep move-
ments and lengthen the sleeping span (Field et al 2002). A 
recent study demonstrated effi cacy with acupressure/pressure 
point massage versus Swedish massage in improving pain 
in fi bromyalgia and chronic pain conditions (Tsao 2007). In 
2007, Mannerkorpi and Henriksson (2007) demonstrated a 
controlled trial of pain relief with massage. Neuromuscular 
therapies (NMT) have shown effi cacy when treating motor 
symptoms like spasticity and rigidity, which can occur 
in FXTAS (Svircev et al 2005). This type of therapeutic 
approach may also help with gait diffi culties seen in FXTAS. 
For the elderly, massage therapies are an important alterna-
tive or additive therapy to pharmacological agents described 
above, particularly when side effects of medications are 
problematic (Sharpe et al 2007).
Psychosocial approaches
Psychoeducation, supportive intervention for the patient and 
their family, and delivering psychiatric care in the context 
of a multidisciplinary team, are all helpful approaches. 
Given the fact that several members in the same family are 
often affected, the intervention may target the patient and 
the family, with consistent longitudinal follow-up being a 
critical component.
Problem-solving therapy (PST) is a therapeutic modality 
which has been shown to improve depressive symptoms and 
functioning in depressed elderly patients with executive dys-
function, and cognitively unimpaired, depressed elderly and 
adults with minor and major depression in the primary care 
setting (Arean et al 1993; Unutzer et al 2002; Alexopoulos 
et al 2003; Haverkamp et al 2004; Steffens et al 2006). In the 
last decade, strong empirical evidence has been gathered to 
support this novel psychotherapy type (Mackin and Arean 
2005). Problem-solving therapy may be used in FXTAS 
patients without dementia, as they have signifi cant executive 
function defi cits (Grigsby et al 2007). Executive dysfunction 
increases the risk of poor response of geriatric depression 
to medications (Alexopoulos et al 2005). By addressing the 
executive dysfunction, the patients’ daily functioning may 
improve and their response to antidepressants will be ampli-
fi ed. Furthermore, the caregivers’ wellbeing may be enhanced 
along with the patients’ mood and anxiety symptoms. Women 
constitute the majority of caregivers for patients with FXTAS 
and 70% of the care-giving population. Women were found 
to have signifi cantly higher odds than male caregivers of hav-
ing a high score on the Zarit Burden Interview (ZBI). Poor 
perceived physical health and more behavior disturbance in 
the patient were associated with higher odds of high levels 
of caregiver burden and depression (Gallicchio et al 2002). 
In our clinical experience depression is very common in the 
wives of men with FXTAS and they typically do well with 
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supportive counseling and the addition of an SSRI agent for 
treatment of their depression.
Genetic counseling
Genetic counseling for FXTAS is complicated. In addition 
to the genetic information and obtaining the family pedigree, 
there are many psychosocial features to be addressed that are, 
themselves, a consequence of the neuropsychiatric features 
(Bourgeois et al 2006; Grigsby et al 2006). When addressing 
the family history, questions regarding neurological, immu-
nological, and endocrine issues must be asked in addition 
to a family history of mental impairment, autism, ADHD, 
behavioral and emotional problems. It is suggested that the 
family history be obtained from the spouse of the patient 
with FXTAS as the patient is likely to be overwhelmed with 
too much information and with recommendations that affect 
quality of life, such as the cessation of driving or need for 
a cane, walker or wheelchair. In addition, the patient may 
not be aware of the severity of his FXTAS-related clinical 
fi ndings and fi nd it depressing and threatening to have these 
addressed. Impotency and incontinence also have the poten-
tial to threaten self-esteem and the genetic counselor needs 
to be aware of and sensitive to all these issues.
The patient with FXTAS cannot be treated in isolation. 
The questions, concerns, and needs of the caregiver/spouse 
must be addressed, as Bacalman and colleagues (2006) 
has shown that these individuals experience varying 
degrees of stress. Therefore, we recommend meeting with 
the caregiver separately from the patient in order to obtain a 
more accurate understanding of the patient’s condition and 
progression and to explore the caregiver’s emotional state and 
understanding of FXTAS. As in Alzheimer disease, the care-
giver is prone to depression, feelings of being overwhelmed, 
grief over the loss of a planned future, anger regarding the 
irritability and lack of support from the patient, and a lack of 
understanding of what the future needs of the patient may be 
(Bacalman et al 2006). The caregiver should be encouraged to 
maintain their own network of friends and activities outside 
of the home so they develop independence and an identity 
beyond that of caregiver. Additionally, the issues of long-
term care must be addressed with the caregiver/spouse as they 
often are not be addressed by the primary care provider.
It is important to end the visit with both the patient and care-
giver present in order to summarize their individual understand-
ing of the issues and to help them to be supportive of each other. 
Mutual intimacy, sensitivity and independence should be encour-
aged as they work in partnership to address FXTAS. Often, a 
genetic counselor must be willing to address these areas.
Conclusions and future directions
A number of medications and therapies have been noted to be 
helpful for the symptoms of FXTAS, although no controlled 
trials of effi cacy have been carried out. Therefore, it is critical 
that controlled trials be undertaken with existing therapeutic 
agents or modalities where anecdotal evidence in patients 
with FXTAS, or controlled studies with related disorders, 
suggests that such approaches would be effi cacious.
Since FXTAS is a progressive neurodegenerative 
disorder, and because none of the current therapies target 
FXTAS pathogenesis, such approaches will, at best, stall or 
transiently improve the symptoms of the disorder. Therefore, 
development of therapeutic interventions that target the 
core molecular processes that underlie FXTAS is essential. 
Such therapeutics would, in principle, target either the 
pathogenic trigger, the expanded-CGG-repeat mRNA itself 
(“toxic RNA”), or downstream pathways that are altered as 
a consequence of the abnormal FMR1 mRNA expression. 
Whereas the simplest approach, conceptually, would be to 
use antisense or RNA interference methods to knock down 
the pathogenic RNA itself, such approaches remain diffi cult 
due to the general inability of such agents to traverse the 
blood brain barrier. However, as we learn more about the 
other molecular abnormalities, and proteins involved, with 
the downstream pathways (Jin et al 2004; Arocena et al 2005; 
Iwahashi et al 2006), additional opportunities for targeted 
interventions will hopefully become available.
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